Press Releases

Ziccum AB (publ) hereby announces that the company has retained Vator Securities AB (“Vator Securities”) to serve as its Certified Adviser. The appointment of Vator Securities as Ziccum's Certified Adviser (CA) shall come into effect on September...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...

Ziccum is pleased to announce that the appellation of its proprietary technology, LaminarPace, has been officially registered with the United States Patent and Trademark Office (USPTO) as a trademark since 23 July 2024. Obtaining trademark protection...

Watch Ziccum CEO Ann Gidner in a comprehensive interview in Swedish with analyst Jonathan Furelid on the highlights of Ziccum’s Q2 2024 report and the company’s current and coming status. CEO Ann Gidner provides investors with updates and...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...

INTERIM REPORT Q2, 1 JANUARY – 30 JUNE 2024 Significant events during Q2 2024 Ziccum strengthens and streamlines business and finance functionsOn April 3, the company announced that it is reorganizing its administrative functions, due to the increased...

Ziccum AB (publ) announces important findings on an increase in mRNA drug activity after LaminarPace treatment and the investigations of the potential mechanisms behind this effect, including the development of a new, unique analytical method to generate...

In a Swedish video interview, Ziccum’s CEO Ann Gidner answers questions from analyst Jonathan Furelid on the topic of business dialogues and agreements. Apart from elaborating on the significance of the recently concluded Feasibility Study Agreement...

Vår VD Ann Gidner svarar på frågor om de uppdateringar bolaget delat gällande den växande portföljen av affärsdialoger den 11 juni, samt ett projektavtal som nu signerats, den 19 juni. Q: Ni kommunicerade den 19 juni...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...

Såsom publicerat 19 juni 2024, har Ziccum AB (publ) tecknat ett avtal med ReCode Therapeutics Inc. (ReCode) beträffande utvärdering av LaminarPace-teknologin. ReCode är ett amerikanskt läkemedelsbolag som utvecklar nästa...

Ziccum AB (publ) has signed an Evaluation Agreement with ReCode Therapeutics, Inc. (ReCode), a US clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, for evaluation of...

Ziccum is continuously engaged in business discussions with potential industrial partners. The status of Ziccum’s project portfolio is presented quarterly in the company interim reports. There are currently further updates to report. Several new...

On 27 April 2021, the Annual General Meeting of Ziccum AB (publ) ("Ziccum" or the "Company") resolved on a directed issue of not more than 46,000 employee stock options of series LTI 2021:1 (the "Stock Options") to certain...

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Ziccum AB (publ) (the “Company”) on the 29th of May 2024 in Lund. Adoption of income statement and balance sheet and discharge from liabilityThe...

Ziccum AB (publ) (”Bolaget”) avhöll den 29 maj 2024 årsstämma i Lund. Vid stämman fattades bland annat följande beslut. Fastställande av årsbokslut och ansvarsfrihetStämman beslutade att fastställa...

Ziccum partners with Dagens Industri, the largest Nordic business paper, to improve shareholders’ access to news updates and raise broader awareness of its continuous scientific and commercial progress. Ziccum AB has signed a partnership with the...

Den 25 april 2024 offentliggjorde Ziccum AB (publ) (”Bolaget”) pressmeddelande innehållande kallelse till Bolagets årsstämma att hållas den 29 maj 2024. I kallelsen angavs att förslag avseende beslut enligt punkterna...

Watch Ziccum CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid on the highlights of Ziccum’s Q1 2024 report and the company’s current and coming status. CEO Ann Gidner provides investors with updates and insights on...

Ziccum AB (publ) (‘Ziccum’) has filed three PCT applications with ample and significant data covering years of equipment development and refinement, process parameter knowledge gained, plus key biopharmaceutical formulation expertise established...